Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - ARYx Therapeutics, Inc. | a10-10002_1ex99d1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 13, 2010
ARYx THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
|
Delaware |
|
001-33782 |
|
77-0456039 |
|
(State or other jurisdiction |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
|
of incorporation) |
|
|
|
|
|
6300 Dumbarton Circle Fremont, California |
|
94555 |
|
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including area code: (510) 585-2200
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02. Results of Operations and Financial Condition.
On May 13, 2010, ARYx Therapeutics, Inc. reported its financial results for the three months ended March 31, 2010. A copy of the press release issued by ARYx on May 13, 2010 is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.
The press release is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by ARYx, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
|
Exhibit Number |
|
Description |
|
99.1 |
|
Press release, dated May 13, 2010, entitled “ARYx Reports First Quarter 2010 Results of Operations — ATI-7505 End of Phase 2 Meeting Held.” |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Dated: May 13, 2010
|
|
|
ARYx THERAPEUTICS, INC. |
|
|
|
|
|
|
|
|
|
|
By: |
/s/ David Nagler |
|
|
|
David Nagler |
|
|
|
Vice President, Corporate Affairs and Secretary |